Organogenesis Holdings Inc. provided earnings guidance for the Fiscal Year 2023. For the year, the company expects Net revenue between $454 million and $466 million, representing an increase of approximately 1% to 3% year-over-year, as compared to net revenue of $450.9 million for the year ended December 31, 2022. Net income between $3 million and $11 million and adjusted net income between $8 million and $16 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.91 USD | +2.28% | +25.76% | -28.97% |
13/05 | Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating | MT |
10/05 | Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.97% | 377M | |
+29.21% | 49.18B | |
+0.84% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.29% | 26.09B | |
-22.70% | 18.71B | |
+8.11% | 13.26B | |
+32.02% | 12.32B | |
-0.63% | 11.99B |
- Stock Market
- Equities
- ORGO Stock
- News Organogenesis Holdings Inc.
- Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year 2023